Troubled Zymergen renegotiates loan, cuts 100 more jobs and loses co-founder
October 21, 2021 at 17:44 PM EDT
The moves are in line with acting CEO Jay Flatley's plans to cut costs at the East Bay synthetic biology company, which just six months ago was a Wall Street darling with a $575 million IPO.
